QuorumCivic. Hidden in plain sight Get the app
Bill intelligence

Pentagon opens biotech R&D pipeline to private companies with minimal public oversight

H.R. 5186 — To authorize the Secretary of Defense to carry out a program to support the defense biotechnology supply chain, and for other purposes. · Filed by Ro Khanna (D-CA) · 2 cosponsors · Introduced Sep 8, 2025 · Referred to committee

65%
Transparency
Typical bill: 82%
35/100
Hidden-provision risk
Typical bill: 15/100
Defense Industrial Policy / Public-Private…

Your members of Congress

Enter a ZIP to see where your representative and both senators stood on this bill.

Looked up on this device — your ZIP is never stored on our servers.

What it does

This bill authorizes the Department of Defense to establish a program supporting the defense biotechnology supply chain by conducting research, developing bio-based materials and fuels, upgrading laboratory infrastructure, and partnering with private companies and universities. The program aims to reduce reliance on foreign suppliers and create a skilled biomanufacturing workforce, with annual reporting to Congress and a 10-year sunset clause (extendable by presidential determination).

Why we flagged it

The bill establishes a federal program to develop biotechnology capabilities for military supply-chain resilience through partnerships with private companies, academic institutions, and federal agencies. It is fundamentally an industrial policy mechanism using defense procurement authority to subsidize and coordinate private biotech development.

What the text implies

  • The bill grants SecDef broad authority to enter into 'contracts, cooperative agreements, grants, or other transactions' with private entities without specifying cost-sharing ratios, intellectual property ownership, or clawback provisions—potentially transferring public R&D investment to private profit.
  • The 'other purposes' language in the title is vague; the bill's scope is limited to biotechnology supply chain, but the phrase may signal additional authorities not detailed in the provided text.

The full analysis lists 5 implications of this text.

Who stands to gain

biotechnology companies (especially those in biomanufacturing and advanced materials); defense contractors with biotech divisions; academic research institutions

Correlative observation from public records — not evidence of coordination or wrongdoing, and not financial advice.
This page is the record as of today. The app tells you when it changes.
Quorum analysis of the full bill text · 119th Congress · public record